Literature DB >> 27208701

Off-target effects of engineered nucleases.

Jiing-Kuan Yee1.   

Abstract

Recent advances in gene editing with engineered nucleases have transformed our ability to manipulate the genome from diverse organisms for applications ranging from biomedical research to disease treatment. A major complication with these engineered nucleases is the binding of the nuclease to unintended genomic sites that share sequence homology with the on-target site. Cleavage of these off-target sites followed by DNA repair using normal cellular DNA repair mechanisms can cause gene mutation or gross chromosome rearrangement. Identification of nuclease-generated off-target sites is a daunting task due to the size and complexity of the mammalian genome. Five unbiased, genome-wide strategies have been developed to detect the off-target cleavage. Some of these strategies reach the sensitivity near the detection limit of directed deep sequencing and have sufficient precision and resolution to objectively assessing the off-target effect of any engineered nuclease. Significant progress has also been made recently to boost the nuclease targeting specificity by protein engineering to modify the structure of the nuclease and alter the interaction with its genomic target. In several studied cases, the off-target effect generated by the modified nuclease is completely eliminated. These modified nucleases significantly improve the overall fidelity of gene editing. These developments will enable gene editing tools to be applied more broadly and safely in basic research and disease treatment.
© 2016 Federation of European Biochemical Societies.

Entities:  

Keywords:  CRISPR/Cas9; engineered nuclease; gene editing; homology-directed repair; meganuclease; nonhomologous end-joining; off-target effect; transcription activator-like effector nuclease; zinc finger nuclease

Mesh:

Substances:

Year:  2016        PMID: 27208701     DOI: 10.1111/febs.13760

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  28 in total

Review 1.  To CRISPR and beyond: the evolution of genome editing in stem cells.

Authors:  Kuang-Yui Chen; Paul S Knoepfler
Journal:  Regen Med       Date:  2016-12-01       Impact factor: 3.806

Review 2.  CRISPR Editing Technology in Biological and Biomedical Investigation.

Authors:  Martyn K White; Rafal Kaminski; Won-Bin Young; Pamela C Roehm; Kamel Khalili
Journal:  J Cell Biochem       Date:  2017-07-04       Impact factor: 4.429

3.  Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human Primates.

Authors:  Xuling Zhu; Ling Yin; Matt Theisen; Jenny Zhuo; Summar Siddiqui; Becca Levy; Vladimir Presnyak; Andrea Frassetto; Jaclyn Milton; Timothy Salerno; Kerry E Benenato; Joe Milano; Andy Lynn; Staci Sabnis; Kristine Burke; Gilles Besin; Christine M Lukacs; Lin T Guey; Patrick F Finn; Paolo G V Martini
Journal:  Am J Hum Genet       Date:  2019-03-14       Impact factor: 11.025

Review 4.  Biosafety of Genome Editing Applications in Plant Breeding: Considerations for a Focused Case-Specific Risk Assessment in the EU.

Authors:  Michael F Eckerstorfer; Marcin Grabowski; Matteo Lener; Margret Engelhard; Samson Simon; Marion Dolezel; Andreas Heissenberger; Christoph Lüthi
Journal:  BioTech (Basel)       Date:  2021-06-22

5.  Mutant Cas9-transcriptional activator activates HIV-1 in U1 cells in the presence and absence of LTR-specific guide RNAs.

Authors:  Veronica Kim; Brian M Mears; Bonita H Powell; Kenneth W Witwer
Journal:  Matters (Zur)       Date:  2017-01-12

6.  CRISPR-mediated Ophthalmic Genome Surgery.

Authors:  Galaxy Y Cho; Yazeed Abdulla; Jesse D Sengillo; Sally Justus; Kellie A Schaefer; Alexander G Bassuk; Stephen H Tsang; Vinit B Mahajan
Journal:  Curr Ophthalmol Rep       Date:  2017-06-15

Review 7.  Modulating gene regulation to treat genetic disorders.

Authors:  Navneet Matharu; Nadav Ahituv
Journal:  Nat Rev Drug Discov       Date:  2020-10-05       Impact factor: 84.694

Review 8.  Selecting a Cell Engineering Methodology During Cell Therapy Product Development.

Authors:  Lauren M Timmins; Alexandra M Burr; Kristina Carroll; Robert Keefe; Matthew Teryek; Louis J Cantolupo; Johannes C M van der Loo; Thomas R J Heathman; Adam Gormley; David Smith; Biju Parekkadan
Journal:  Cell Transplant       Date:  2021 Jan-Dec       Impact factor: 4.064

9.  Role of circadian gene Clock during differentiation of mouse pluripotent stem cells.

Authors:  Chao Lu; Yang Yang; Ran Zhao; Bingxuan Hua; Chen Xu; Zuoqin Yan; Ning Sun; Ruizhe Qian
Journal:  Protein Cell       Date:  2016-09-23       Impact factor: 14.870

10.  Prediction and validation of hematopoietic stem and progenitor cell off-target editing in transplanted rhesus macaques.

Authors:  Aisha A AlJanahi; Cicera R Lazzarotto; Shirley Chen; Tae-Hoon Shin; Stefan Cordes; Xing Fan; Isabel Jabara; Yifan Zhou; David J Young; Byung-Chul Lee; Kyung-Rok Yu; Yuesheng Li; Bradley Toms; Ilker Tunc; So Gun Hong; Lauren L Truitt; Julia Klermund; Geoffroy Andrieux; Miriam Y Kim; Toni Cathomen; Saar Gill; Shengdar Q Tsai; Cynthia E Dunbar
Journal:  Mol Ther       Date:  2021-06-24       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.